GVAG
IMRX icon

Great Valley Advisor Group’s Immuneering IMRX Stock Holding History

Great Valley Advisor Group’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$112K Buy
21,120
+2,120
+11% +$10.9K ﹤0.01% 974
2025
Q4 		$125K Buy
+19,000
New +$122K ﹤0.01% 920

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $165M AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Great Valley Advisor Group's IMRX Position: Q1 2026 in Review

Great Valley Advisor Group increased its Immuneering (IMRX) stake by 11% in Q1 2026, buying an estimated $10.9K and bringing the position to 21,120 shares worth $112K. The position accounts for ﹤0.01% of the portfolio, ranked #974.

Great Valley Advisor Group first reported a position in IMRX in Q4 2025 and has held it in 2 quarters since. The position peaked at $125K in Q4 2025. 95 funds tracked by Wall St. Rank hold IMRX as of Q1 2026.

  • Great Valley Advisor Group held 21,120 shares of Immuneering worth $112K as of Q1 2026.
  • Great Valley Advisor Group bought 2,120 Immuneering shares in Q1 2026, an estimated $10.9K.
  • Immuneering made up ﹤0.01% of Great Valley Advisor Group's portfolio in Q1 2026, its #974 holding.
  • Great Valley Advisor Group first reported a position in Immuneering in Q4 2025 and has held it in 2 quarters since.
  • Great Valley Advisor Group's Immuneering position peaked at $125K in Q4 2025.
  • 95 funds tracked by Wall St. Rank held Immuneering as of Q1 2026.

Based on Great Valley Advisor Group's 13F filing for Q1 2026, filed 11 May 2026.